Clinical trials: Partial Response
Gastrointestinal Stromal Tumors
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST
- Trial name
- NCT00441155
- Testing
- Nilotinib, Imatinib
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
PBC
Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that eventually leads to end-stage liver failure and death unless liver transplantation (LT) is performed.
- Trial name
- BEZURSO (NCT01654731)
- Testing
- Bezafibrate
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Full Spectrum
A Self-controlled Study of the Effect of Partial Spectral Absence of Visible Light on the Pupil
Previous studies have shown that the spectrum of light influences myopia. LED lights with a partially absent light spectrum increase the risk of myopia progression compared to LEDs with a full spectrum, potentially mediated by…
- Trial name
- NCT06501131
- Testing
- full-spectrum light exposure, specific spectrum absence light exposure
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Breast Cancer
Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.
Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.
- Trial name
- ATD (NCT06272799)
- Testing
- T-DM1 adjuvant
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Regina Elena Cancer Institute
Temporal Lobe Epilepsy
Autonomic Dysfunction in Temporal Lobe Epilepsy and SUDEP
The study aimed at detection of autonomic dysfunction among cases with temporal lobe epilepsy; using different electrophysiological techniques.
- Trial name
- NCT06269822
- Testing
- Sympathetic skin response, heart rate variability test, quantitative EEG
- Where
- Egypt
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cairo University
Major Depressive Disorder
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit
- Trial name
- VIVRE (NCT04448431)
- Testing
- Vortioxetine, Desvenlafaxine
- Where
- 80 sites in Argentina, Belgium and 10 more
- Volunteers
- 605 people
- Sponsor
- H. Lundbeck A/S
Primary Biliary Cirrhosis
Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
The purpose of this protocol is to conduct a trial in a selected population of patients with PBC based on an incomplete biochemical response after 12 months of UDCA therapy.
- Trial name
- NCT02965911
- Testing
- Fenofibrate, UDCA
- Where
- China
- Sponsor
- Beijing 302 Hospital
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Lung Cancer, CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
TF2- Small Cell Lung Cancer Radio Immunotherapy
Lung cancer is currently the leading cause of cancer death in both men and women in Europe, with an estimated 250000 new cases diagnosed in 2005.
- Trial name
- NCT01221675
- Testing
- Antibody TF2, IMP-288-Lutetium, IMP-288-Indium
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre René Gauducheau
HIV Infections
A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
Our goal is to determine if a change in therapy to one containing Kaletra can improve the immune response in patients who have previously been immune partial responders or non-responders.
- Trial name
- NCT00145795
- Testing
- Kaletra + Current Dual NRTI Backbone, Current Regimen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Sepsis - to Reduce Mortality in the Intensive Care Unit, Septic Shock
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock
Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem.
- Trial name
- CARBON (NCT07179276)
- Testing
- CO2gap-guided resuscitation strategy
- Where
- 28 sites in France
- Volunteers
- 750 people
- Sponsor
- University Hospital, Clermont-Ferrand
Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma
Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and safety of MDV9300 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have achieved either stable disease or a partial remission following…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma, Transformed Indolent Lymphoma
- Trial name
- NCT02653989
- Testing
- MDV9300
- Where
- United States
- Sponsor
- Medivation, Inc.
Hepatitis C
Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin
This is a 60-to-72 week multicenter study to evaluate Infergen and Ribavirin in patients with Chronic Hepatitis C Virus after partial response to treatment using peginterferon-alfa and Ribavirin therapy.
- Trial name
- ENHANCE (NCT00456248)
- Testing
- Infergen and ribavirin
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Kadmon Corporation, LLC
Carcinoma, Hepatocellular
SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT).
- Trial name
- NCT02221778
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- University of Sao Paulo
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
RGL-305+ Lymphoma + Exploratory Clinical Study
This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma.
- Trial name
- NCT07006012
- Testing
- RGL-305
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE (bortezomib) in patients with multiple myeloma with detectable disease…
- Trial name
- NCT00311337
- Testing
- bortezomib
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 61 people
- Sponsor
- University of Wuerzburg
Chronic Obstructive Pulmonary Disease
Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)
Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.
- Trial name
- NCT01068145
- Testing
- SCH 527123
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel
This study will examine the clinical response, cytokine expression and joint imaging after addition of Acthar Gel. The hypothesis is that H.P.
- Trial name
- NCT03082573
- Testing
- H.P. Acthar gel
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Iraj Sabahi Research Inc.